Articles

Cardiovascular benefit of evolocumab in 27,564 patients with and without autoimmune or inflammatory diseases: an analysis of the fourier trial

7. Zimerman A, Robert P. Ana KG, et al.

Journal: 

JACC

First published: April 5, 2024  DOI: 10.1016/S0735-1097(24)03672-6

Abstract


Full Article